potassium chloride replacement

ApprovedSmall molecule

BBaptist Health South Florida

potassium chloride replacement is one of 3 small molecule programs targeting Phlebitis. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

PhlebitisActive, not recruiting

PhlebitisApproved

Active, not recruiting

Competition

Competitive Landscape

4 competitors in Phlebitis

#DrugCompanyPhaseTrials

Olux

HHarrow Inc

Phase 2

1 2

potassium chloride replacement

BBaptist Health South Florida

Approved

1 3

Nitrostat

VViatris Specialty LLC

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Phlebitis1 trial

The Impact of Neut During Potassium Chloride Replacement on Pain and Incidence of Phlebitis

Terminated·BBaptist Health South Florida·Phase 4·NCT02082717·17 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for potassium chloride replacement. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — potassium chloride replacement compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for potassium chloride replacement. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Baptist Health South Florida company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: BBaptist Health South Florida

potassium chloride replacement

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Phlebitis1 trial

References

Drug Info

Quick Facts

Related News